Dual targeted nanocarrier for brain ischemic stroke treatment.
Dual targeted nanocarrier for brain ischemic stroke treatment.
复制标题
DOI：
10.1016/j.jconrel.2016.04.038
复制
发表时间：
2016-07
期刊：
影响因子：
--
通讯作者：
Yue Zhao;Yan Jiang;Wei Lv;Zhongyuan Wang;Lingyan Lv;Baoyan Wang;Xin Liu;Yang Liu;Quanyin Hu;Wujin Sun;Qunwei Xu;Hongliang Xin;Zhen Gu
中科院分区：
文献类型：
--
作者：
Yue Zhao;Yan Jiang;Wei Lv;Zhongyuan Wang;Lingyan Lv;Baoyan Wang;Xin Liu;Yang Liu;Quanyin Hu;Wujin Sun;Qunwei Xu;Hongliang Xin;Zhen Gu
Focal cerebral ischemia, known as stroke, causes serious long-term disabilities globally. Effective therapy for cerebral ischemia demands a carrier that can penetrate the blood-brain barrier (BBB) and subsequently target the ischemia area in brain. Here, we designed a novel neuroprotectant (ZL006) loaded dual targeted nanocarrier based on liposome (T7&SHp-P-LPs/ZL006) conjugated with T7 peptide (T7) and stroke homing peptide (SHp) for penetrating BBB and targeting ischemia area, respectively. Compared with non-targeting liposomes, T7&SHp-P-LPs/ZL006 could transport across BCEC cells and significantly enhance cellular uptake and reduce cells apoptosis of excitatory amino acid stimulated PC-12 cells. However, there was no significant difference in cellular uptake between SHp-modified and plain liposomes when PC-12 cells were incubated without excitatory amino acid. Besides,ex vivofluorescent images indicated that DiR labeled T7&SHp-P-LPs could efficiently transport across BBB and mostly accumulated in ischemic region rather than normal cerebral hemisphere of MCAO rats. Furthermore, T7&SHp-P-LPs/ZL006 could enhance the ability ofin vivoanti-ischemic stroke of MCAO rats. These results demonstrated that T7&SHp-P-LPs could be used as a safe and effective dual targeted nanocarrier for ischemic stroke treatment.
